The widening net loss and massive dilution from the $12M private placement at $0.06/share (200M shares + 200M warrants) create severe downward pressure on the stock. Monitor for Nasdaq compliance updates on the bid-price deficiency and any goodwill impairment triggers given the $360M goodwill balance relative to a $117M market cap.
Price Chart
Executive Summary
BGM Group Ltd. reported H1 FY2026 (six months ended March 31, 2026) results showing a 70% YoY revenue increase to $24.3M, driven entirely by newly acquired AI solutions ($2.2M) and insurance ($5.9M) segments, while the core pharmaceutical business grew 68% to $16.2M. However, net loss attributable to shareholders widened 144% to $2.1M from $0.9M, with operating cash flow turning positive at $2.5M vs. -$3.1M a year ago. The massive share dilution from prior stock-for-asset acquisitions (over 172M shares) and a subsequent $12M private placement at $0.06/share (200M new shares + 200M warrants) severely overhang the stock, while the company faces ongoing Nasdaq bid-price deficiency risk.
Key Facts
- Revenue grew 70% YoY to $24.3M, but net loss attributable to BGM widened 144% to $2.1M.
- Core pharmaceutical segment revenue grew 68% to $16.2M; AI solutions and insurance contributed $2.2M and $5.9M respectively.
- Operating cash flow improved to +$2.5M from -$3.1M in prior year period.
- Goodwill ballooned to $360.3M (82% of total assets) from $350.8M, reflecting stock-for-asset acquisitions.
- Subsequent private placement of 200M shares at $0.06/share plus warrants for 200M more (May 2026) will massively dilute existing holders.
- Accumulated deficit grew to $17.9M from $15.8M; total shareholders' equity is $399.8M vs. market cap of $117M.
Financial Impact
Net loss of $2.1M on $24.3M revenue; $360M goodwill at risk of impairment; $12M dilutive private placement at $0.06/share
Risk Factors
- Nasdaq delisting risk from bid-price deficiency
- Goodwill impairment risk ($360M vs $117M market cap)
- Massive shareholder dilution from recent and pending share issuances
- Core pharmaceutical business may face continued pricing pressure
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-102847 |
| Document: 0001104659-26-102847-index-headers.html | 0001104659-26-102847 |
| Document: 0001104659-26-102847-index.html | 0001104659-26-102847 |
| Document: 0001104659-26-102847.txt | 0001104659-26-102847 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 28, 2026 5w ago | 6-K | $0.3275 $0.2440 | ▲ +25.50% | ▲ +25.76% | $9.34 (−2751.91%) |
Jul 21, 2026 10w ago | 20-F | $0.3000 $0.2880 | ▲ +4.00% | ▲ +6.56% | $9.34 (−3013.33%) |
Jun 9, 2026 16w ago | 6-K | $0.3401 $0.3332 | ▲ +2.03% | ▲ +3.48% | $9.34 (−2646.25%) |
May 18, 2026 19w ago | 6-K | $0.2750 $0.4441 | ▼ −61.49% | ▼ −59.91% | $9.34 (−3296.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access